Diagnosing Group A Strep pharyngitis - Which Technique is Best for You?

Gregory J. Berry, Ph.D., D(ABMM)
Assistant Professor, Pathology and Laboratory Medicine
Zucker School of Medicine at Hofstra/Northwell
Director, Molecular Diagnostics/ Asst. Director, Infectious Disease Diagnostics
Northwell Health Laboratories

March 27, 2018
Learning objectives

Review the clinical background of Group A Strep and its role as a pathogen in human health

Identify various ways in which Group A Strep pharyngitis can be accurately diagnosed

Discuss testing recommendations for Group A Strep pharyngitis

Explore aspects that influence which test(s) are the best fit for a clinic/health system
Streptococcus pyogenes (group A strep - GAS)

- Lancefield Group A serogrouping: “group A strep”

- Beta hemolytic (complete hemolysis) on blood agar plate: “β strep”

- Responsible for a wide range of human infections
  - Some individuals are carriers

https://www.slideshare.net/AshleyHamilton11/clinical-microbiology-53574911
GAS as a human pathogen

• Responsible for many different infections
  – Range from minor illness to deadly infections

• Common cause of “strep throat” pharyngitis, impetigo, scarlet fever
  – Serious secondary complications include rheumatic fever, rheumatic heart disease, and glomerulonephritis

• Can also cause life-threatening invasive infections
GAS - Then and Now

• Illness was likely first described by Hippocrates in 400 BC
  – Erysipelas (red skin) and other symptoms

• In the late 1880s and early 1900s scarlet fever was the leading cause of death in children

• Incidence rapidly declined in the 20th century

• Rapid resurgence in the UK - 2016 saw highest number of cases in almost 50 years
  – Cases also increasing steadily in East Asia

---

1 Ferretti, Joseph; Kohler, Werner (February 2016). "History of Streptococcal Research". Streptococcus pyogenes: Basic Biology to Clinical Manifestations. PMID 26866232
2 BMJ 2016;352:i1658

How do you get infected?

• GAS resides in the nose and throat of infected individuals

• Typically spread through person-to-person contact
  – Daycare centers, schools, military training facilities

• Bacteria can travel in respiratory droplets and nasal secretions that get expelled during coughing, sneezing, etc.

Good hygiene is the best way to prevent infection
Pharyngitis

• “Sore throat”

• Most common upper respiratory tract infection

• Inflammation of the back of the throat (pharynx)
  – Can also cause runny nose, cough, fever

• Typical duration: 3 - 5 days

• Majority of cases are viral, but can also be bacterial
  – Viral- typically self-limiting
  – Bacterial- treatment options available

https://upload.wikimedia.org/wikipedia/commons/b/b1/Pharyngitis.jpg
<table>
<thead>
<tr>
<th>Organisms</th>
<th>Clinical Syndrome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial</strong></td>
<td></td>
</tr>
<tr>
<td>Group A streptococcus</td>
<td>Pharyngotonsillitis, scarlet fever</td>
</tr>
<tr>
<td>Group C and group G streptococcus</td>
<td>Pharyngotonsillitis</td>
</tr>
<tr>
<td>Arcanobacterium haemolyticum</td>
<td>Scarlatiniform rash, pharyngitis</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>Tonsillopharyngitis</td>
</tr>
<tr>
<td>Corynebacterium diphtheriae</td>
<td>Diphtheria</td>
</tr>
<tr>
<td>Mixed anaerobes</td>
<td>Vincent’s angina</td>
</tr>
<tr>
<td>Fusobacterium necrophorum</td>
<td>Lemierre’s syndrome, peritonsillar abscess</td>
</tr>
<tr>
<td>Francisella tularensis</td>
<td>Tularemia (oropharyngeal)</td>
</tr>
<tr>
<td>Yersinia pestis</td>
<td>Plague</td>
</tr>
<tr>
<td>Yersinia enterocolitica</td>
<td>Enterocolitis, pharyngitis</td>
</tr>
<tr>
<td><strong>Viral</strong></td>
<td></td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Pharyngoconjunctival fever</td>
</tr>
<tr>
<td>Herpes simplex virus 1 and 2</td>
<td>Gingivostomatitis</td>
</tr>
<tr>
<td>Coxsackievirus</td>
<td>Herpangina</td>
</tr>
<tr>
<td>Rhinovirus</td>
<td>Common cold</td>
</tr>
<tr>
<td>Coronavirus</td>
<td>Common cold</td>
</tr>
<tr>
<td>Influenza A and B</td>
<td>Influenza</td>
</tr>
<tr>
<td>Parainfluenza</td>
<td>Cold, croup</td>
</tr>
<tr>
<td>EBV</td>
<td>Infectious mononucleosis</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>CMV mononucleosis</td>
</tr>
<tr>
<td>HIV</td>
<td>Primary acute HIV Infection</td>
</tr>
<tr>
<td><strong>Mycoplasma</strong></td>
<td></td>
</tr>
<tr>
<td>Mycoplasma pneumoniæ</td>
<td>Pneumonitis, bronchitis</td>
</tr>
<tr>
<td><strong>Chlamydia</strong></td>
<td></td>
</tr>
<tr>
<td>Chlamydia pneumoniæ</td>
<td>Bronchitis, pneumonia</td>
</tr>
<tr>
<td>Chlamydia psittaci</td>
<td>Psittacosis</td>
</tr>
</tbody>
</table>

**Abbreviations:** CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus.
GAS pharyngitis

• Most common bacterial cause of pharyngitis

• Seasonality: winter and early spring

• Clinical manifestation
  – Rapid onset sore throat
  – Painful swallowing
  – Red, swollen tonsils
  – White patches/streaks of pus
  – Petechiae on roof of mouth
  – Swollen lymph nodes
  – Fever
  – Headache, abdominal pain, nausea, vomiting


© Copyright 2016, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.
GAS pharyngitis

- Can be accompanied by scarlatiniform rash - scarlet fever or scarlatina.
  "Strawberry tongue"

- Incubation period: 2-5 days

- Most common in children 5-15 years of age, uncommon under age 3

- Costs to US economy - $224-$539 million/yr

### Table 4. Epidemiologic and Clinical Features Suggestive of Group A Streptococcal and Viral Pharyngitis

<table>
<thead>
<tr>
<th>Feature, by Suspected Etiologic Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GROUP A STREPTOCOCCAL</strong></td>
</tr>
</tbody>
</table>
| • Sudden onset of sore throat  
• Age 5–15 years  
• Fever  
• Headache  
• Nausea, vomiting, abdominal pain  
• Tonsillopharyngeal inflammation  
• Patchy tonsillopharyngeal exudates  
• Palatal petechiae  
• Anterior cervical adenitis (tender nodes)  
• Winter and early spring presentation  
• History of exposure to strep pharyngitis  
• Scarlatiniform rash |
| **VIRAL** |
| • Conjunctivitis  
• Coryza  
• Cough  
• Diarrhea  
• Hoarseness  
• Discrete ulcerative stomatitis  
• Viral exanthema |
# Treatment for GAS pharyngitis

<table>
<thead>
<tr>
<th>Drug, Route</th>
<th>Dose or Dosage</th>
<th>Duration or Quantity</th>
<th>Recommendation Strength, Quality(^a)</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For individuals without penicillin allergy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin V, oral</td>
<td>Children: 250 mg twice daily or 3 times daily; adolescents and adults: 250 mg 4 times daily or 500 mg twice daily</td>
<td>10 d</td>
<td>Strong, high</td>
<td>[125, 126]</td>
</tr>
<tr>
<td>Amoxicillin, oral</td>
<td>50 mg/kg once daily (max = 1000 mg); alternate: 25 mg/kg (max = 500 mg) twice daily</td>
<td>10 d</td>
<td>Strong, high</td>
<td>[88–92]</td>
</tr>
<tr>
<td>Benzathine penicillin G, intramuscular</td>
<td>&lt;27 kg: 600 000 U; ≥27 kg: 1 200 000 U</td>
<td>1 dose</td>
<td>Strong, high</td>
<td>[53, 125, 127]</td>
</tr>
<tr>
<td>For individuals with penicillin allergy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cephalexin,(^b) oral</td>
<td>20 mg/kg/dose twice daily (max = 500 mg/dose)</td>
<td>10 d</td>
<td>Strong, high</td>
<td>[128–131]</td>
</tr>
<tr>
<td>Cefadroxil,(^b) oral</td>
<td>30 mg/kg once daily (max = 1 g)</td>
<td>10 d</td>
<td>Strong, high</td>
<td>[132]</td>
</tr>
<tr>
<td>Clindamycin, oral</td>
<td>7 mg/kg/dose 3 times daily (max = 300 mg/dose)</td>
<td>10 d</td>
<td>Strong, moderate</td>
<td>[133]</td>
</tr>
<tr>
<td>Azithromycin,(^c) oral</td>
<td>12 mg/kg once daily (max = 500 mg)</td>
<td>5 d</td>
<td>Strong, moderate</td>
<td>[97]</td>
</tr>
<tr>
<td>Clarithromycin,(^c) oral</td>
<td>7.5 mg/kg/dose twice daily (max = 250 mg/dose)</td>
<td>10 d</td>
<td>Strong, moderate</td>
<td>[134]</td>
</tr>
</tbody>
</table>

Abbreviation: Max, maximum.

\(^a\) See Table 1 for a description.

\(^b\) Avoid in individuals with immediate type hypersensitivity to penicillin.

\(^c\) Resistance of GAS to these agents is well-known and varies geographically and temporally.


© Copyright 2016, Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health.
Clinical Laboratory Standards Institute (CLSI) guidelines M100 28th edition:

• Streptococcus spp. footnote n: “Penicillin and ampicillin are the drugs of choice for treating β-hemolytic streptococcal infections. Susceptibility testing of penicillins and other β-lactams approved by the US Food and Drug Administration for treating β-hemolytic streptococcal infections does not need to be performed routinely, because nonsusceptible isolates…are extremely rare in any β-hemolytic streptococci and have not been reported for Streptococcus pyogenes.”
Testing Methodologies for GAS Detection
No matter the test, proper specimen collection is critical

1. Have the patient tilt their head backwards, open mouth, and stick out tongue.

2. Use tongue depressor to hold the tongue in place.

3. Without touching the sides of the mouth, swab the posterior nasopharynx and the tonsillar arches.

4. Insert swab into sterile transport system.

5. Deliver samples to laboratory for testing.
## Testing for GAS pharyngitis

### Testing in clinic (Point of Care)
- Rapid antigen tests
- Molecular nucleic acid amplification testing (POCT)

### Laboratory Testing
- Throat culture
- Molecular nucleic acid amplification
What determines where the test can be performed?
CLIA regulations for testing

- All laboratory testing in the U.S. falls under the jurisdiction of Clinical Laboratory Improvement Amendments of 1988 (CLIA)

- Administered by CMS and is implemented through three federal agencies—CDC, CMS, and the Food and Drug Administration (FDA)

- The three categories of testing for CLIA purposes are waived, moderate complexity (including the provider-performed microscopy procedures [PPMP] subcategory), and high complexity
CLIA regulations for testing

- Waived, moderate complexity, and high complexity designation based on ease of use
- CLIA requires that waived tests must be simple and have a low risk for erroneous results
- Tests classified as moderately complex must be performed in a clinical laboratory

Only CLIA-waived tests can be performed at point-of-care
Point-of-care testing (POCT)

Testing performed while patient care is occurring

Main advantage is time gained

Therapeutic choices in real time
• Identify treatment to administer
• Avoid unnecessary drugs/treatments

Requires simple platforms with accurate results

https://i.pinimg.com/736x/0c/26/a9/0c26a969cd5be705139c9a71f39e3665--point-of-care-testing-lab-tech.jpg
POCT in infectious disease diagnostics

- These are CLIA waived tests that can be performed by facilities with a Certificate of Waiver
- Increasingly larger portion of infectious disease testing
- Huge advantage of rapid answer for treatment decisions
- Quality is key - results must approach the same sensitivity and specificity of laboratory tests
Rapid antigen tests for GAS

- Available since the 1980s
- Most common first line of testing at clinic
- Immunoassays: detect GAS-specific antigens
- Qualitative resulting
- Vary greatly in their sensitivity
  - Negative GAS results need culture confirmation
Rapid antigen detection test for group A streptococcus in children with pharyngitis

Jérémie F Cohen, Nathalie Bertille, Robert Cohen, Martin Chalumeau

1 Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPE), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS), Inserm UMR1153, Paris Descartes University, Paris, France. 2 Department of Pediatrics, Necker Hospital, AP-HP and Paris Descartes University, Paris, France. 3 Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Saint-Maur-des-Fossés, France. 4 Department of Microbiology, Centre Hospitalier Intercommunal de Créteil (CHIC), Créteil, France

Contact address: Martin Chalumeau, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPE), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS), Inserm UMR1153, Paris Descartes University, Paris, France.
martin.chalumeau@gmail.com, martin.chalumeau@nck.aphp.fr

Editorial group: Cochrane Acute Respiratory Infections Group.
Review content assessed as up-to-date: .

ABSTRACT

Background

Group A streptococcus (GAS) accounts for 20% to 40% of cases of pharyngitis in children; the remaining cases are caused by viruses. Compared with throat culture, rapid antigen detection tests (RADTs) offer diagnosis at the point of care (within five to 10 minutes).

Objectives

To determine the diagnostic accuracy of RADTs for diagnosing GAS in children with pharyngitis. To assess the relative diagnostic accuracy of the two major types of RADTs (enzyme immunoassays (EIA) and optical immunoassays (OIA)) by indirect and direct comparison.

Search methods

We searched CENTRAL, MEDLINE, EMBASE, Web of Science, CDSR, DARE, MEDION and TRIP (January 1980 to July 2015). We also conducted related citations tracking via PubMed, handsearched reference lists of included studies and relevant review articles, and screened all articles citing included studies via Google Scholar.

Selection criteria

We included studies that compared RADT for GAS pharyngitis with throat culture on a blood agar plate in a microbiology laboratory in children seen in ambulatory care.

Data collection and analysis

Two review authors independently screened titles and abstracts for relevance, assessed full texts for inclusion, and carried out data extraction and quality assessment using the QUADAS-2 tool. We used bivariate meta-analysis to estimate summary sensitivity and specificity, and to investigate heterogeneity across studies. We compared the accuracy of EIA and OIA tests using indirect and direct evidence.
Study characteristics

We searched for studies published in any language from January 1980 to July 2015. We found 98 unique studies, for a total of 116 test evaluations, involving 101,121 children. The number of participants ranged from 42 to 11,644 across test evaluations. The proportion of children with strep throat ranged from 9.5% to 66.6% across test evaluations.

Quality of the evidence

Important study design features were frequently not reported. The overall methodological quality of included studies was poor. For most studies, we had concerns about the ways in which participants were selected.
Key results

On average, rapid tests for strep throat had a **sensitivity (ability to correctly detect people with the disease)** of 86% and a **specificity (ability to correctly identify people who do not have the disease)** of 95%. There was substantial variability in rapid test performance across studies, which was not explained by study characteristics, including methodological quality. The two types of rapid tests under evaluation seemed to have comparable sensitivity (85.4% versus 86.2% for enzyme immunoassays and optical immunoassays, respectively). Based on these results, we would expect that amongst 100 children with strep throat, 86 would be correctly detected with the rapid test while 14 would be missed and not receive antibiotic treatment. Of 100 children with non-streptococcal sore throat, 95 would be correctly classified as such with the rapid test while 5 would be misdiagnosed as having strep throat and receive unnecessary antibiotics.
Notes from the Field

Group A Streptococcal Pharyngitis Misdiagnoses at a Rural Urgent-Care Clinic — Wyoming, March 2015

Alexia Harrist, MD, PhD; Clayton Van Houten, MS; Stanford T. Shulman, MD; Chris Van Beneden, MD; Tracy Murphy, MD

Group A Streptococcus (GAS) is the most common bacterial cause of pharyngitis, implicated in 20%–30% of pediatric and 5%–15% of adult health care visits for sore throat (1). Along with the sudden onset of throat pain, GAS pharyngitis symptoms include fever, headache, and bilateral tender cervical lymphadenopathy (1,2). Accurate diagnosis and management of GAS pharyngitis is critical for limiting antibiotic overuse and preventing rheumatic fever (2), but distinguishing between GAS and viral pharyngitis clinically is challenging (1). Guidelines for diagnosis and management of GAS pharyngitis have been published by the Infectious Diseases Society of America (IDSA)* (1). IDSA recommends that patients with sore throat be tested for GAS to distinguish between GAS and viral pharyngitis; however, IDSA emphasizes the use of selective testing based on clinical symptoms and signs to avoid identifying GAS carriers rather than acute GAS infections (1). Therefore, testing for GAS usually is not recommended for the following: patients with sore throat and accompanying symptoms of GAS pharyngitis reported no sore throat, the symptom that should prompt evaluation for GAS pharyngitis in patients aged ≥3 years (1). Two of these 10 were asymptomatic adult contacts of patients with diagnosed GAS pharyngitis; both asymptomatic contacts had positive RADT results and were prescribed an antibiotic. Of the 24 tested patients aged ≥3 years with sore throat, 19 (79%) reported cough or rhinorrhea, symptoms that suggest a viral rather than bacterial etiology (1). Although diagnostic testing of patients aged <3 years is not routinely recommended, testing of symptomatic children who are household contacts of persons with laboratory-confirmed GAS pharyngitis can be considered (1). Among the seven patients aged <3 years who were tested for GAS pharyngitis, five (71%) had GAS-positive family members indicated by shared surname included in the line list; however, all seven (100%) had cough, and five (71%) had rhinorrhea.

Four of six patients with negative RADT results received an antibiotic. The clinic practice was to send throat swabs from patients with negative RADTs to a commercial laboratory for back-up culture, but it is unknown whether the clinic obtained any GAS-positive throat cultures from RADT-negative patients.
Investigation

- In March 2015, a rural urgent-care clinic serving a population of 5,000–7,000 reported a substantial increase in GAS pharyngitis infections since November 2014, with some infections nonresponsive to penicillin and amoxicillin to the Wyoming Department of Health (WDH).

- Findings
  - Testing asymptomatic patients (no sore throat)
  - Testing of patients with viral illness symptoms
  - 86% positivity rate on rapid antigen tests performed
  - Clinic staff were reading tests at longer intervals than manufacturer’s instructions - can lead to false positives

- Intervention
  - Cases declined, no resistance was found - likely viral illnesses misdiagnosed as GAS

Follow the FDA approved package insert
Molecular POCT
Historical impediments to POCT

• Not accurate enough for definitive diagnosis  
  – E.g. rapid strep and flu tests

• Too difficult to perform at point-of-care  
  – E.g. molecular testing

• Too Expensive
How does Molecular POCT address these issues?

<table>
<thead>
<tr>
<th>Problems</th>
<th>Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Not accurate enough for definitive diagnosis</td>
<td>• Increasing sensitivity and specificity</td>
</tr>
<tr>
<td>– E.g. rapid strep and flu tests</td>
<td>– Molecular testing</td>
</tr>
<tr>
<td>• Too difficult to perform at point-of-care</td>
<td>• Assays designed to be user-friendly and more</td>
</tr>
<tr>
<td>– E.g. molecular testing</td>
<td>error-proof</td>
</tr>
<tr>
<td>• Too Expensive</td>
<td>• Costs decreasing over time and reimbursement</td>
</tr>
</tbody>
</table>
Molecular POCT tests for infectious diseases

• Traditionally designated by CLIA as moderate/high complexity
  – performed in the clinical laboratories

• Only rapid antigen testing was available as CLIA waived

• CLIA waived tests have recently become available
CLIA waived molecular tests for infectious diseases

• **January 8th, 2015:** First CLIA waived test for influenza A and B (Alere i Influenza A&B)

• Followed by the Roche cobas Influenza A/B

• **GAS** and RSV are also now available on both platforms
<table>
<thead>
<tr>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can amplify genome</td>
<td>Typically costs more</td>
</tr>
<tr>
<td>Highly sensitive and specific</td>
<td>Takes longer</td>
</tr>
</tbody>
</table>

Molecular testing pros and cons
Advantage of sample amplification

Detection threshold

Amplified GAS+ Sample

Not Amplified GAS+ Sample

Nurse A

Nurse B
Alere™ i

4 - 8 minutes to result for GAS

8-13 minutes to result for Flu/RSV

Small footprint (8.15” W x 5.71” H x 7.64” D)

Weight= 1.4 lbs / 3 kg
LIAT - Lab In a Tube

- 15 minutes to results GAS
- 20 minutes to results Flu/ RSV
- Footprint 4.5 x 9.5 x 7.5
- Weight 8.3 lbs
Laboratory testing

• Testing performed in centralized location

• Lab is licensed and accredited to perform patient testing

• Licensed laboratory personnel perform testing
Laboratory Workup for GAS
Identification of GAS by culture

- Throat swab is collected and inoculated onto plates
  - Most laboratories are routinely identifying only GAS
    - Agar selective for strep, or BAP can be used with a bacitracin (A) disk
      - GAS is susceptible to bacitracin
      - Catalase (-); PYR(+); MALDI-TOF can also be used for identification
    - Additional workup can be done if other pathogens suspected
      - e.g. blood agar for other streptococci (B, C, F, G) and A. haemolyticum, or modified Thayer-Martin for N. gonorrhoeae isolation

- Incubate in aerobic incubator with 5% CO₂

- Result: 24-48 hours
Beta hemolysis

Photo courtesy of Dr. Lesley McGee, CDC
Bacitracin (A) disk and GAS

Susceptible zone of inhibition

https://microbeonline.com/wp-content/uploads/2013/05/Bacitracin-disk-test-for-Streptococcus-pyogenes.jpg
GAS PCR

• Literature shows PCR is just as sensitive, or more sensitive than standard culture

• Advantage for clinician- rapid turnaround time (hours vs. 1-3 days)

• Time can offer huge advantage of choosing the right therapeutic therapy up-front
LYRA® Direct Strep Assay

Quidel: Real-Time PCR

Detection and differentiation of GAS and group C/G Streptococcus

Batching of specimens

~70 minute result
ARIES® Group A Strep Assay

- Luminex: Real-Time PCR
- Detection of GAS
- Batching: 2 drawers, 6 specimens each
- ~ 2 hours
Xpert® Xpress Strep A

Cepheid: Real-Time PCR

Detection of GAS

Each specimen runs independently

24 minutes, or less
illumigene Group A Streptococcus DNA Amplification Assay

Meridian Bioscience: Loop-mediated Isothermal DNA amplification

Detection of GAS

Each specimen runs independently

>1 hour
## Comparison of Methods

<table>
<thead>
<tr>
<th>Feature</th>
<th>Rapid antigen</th>
<th>Culture</th>
<th>Laboratory Molecular</th>
<th>POCT Molecular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fast</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Convenient</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Actionable results</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>POCT- friendly</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Little/No subjectivity</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>LIS/EMR interfaced</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>High sensitivity/specificity</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Low Cost</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America


1Department of Pediatrics, Division of Infectious Diseases, Ann & Robert H. Lurie Children’s Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois; 2Department of Medicine, University of Miami Miller School of Medicine, Miami Veterans Affairs Healthcare System, Miami, Florida; 3Department of Pediatrics, Hemby Children’s Hospital and Eastover Pediatrics, Charlotte, North Carolina; 4Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 5Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota; 6Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts; 7Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania; and 8Respiratory Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

The guideline is intended for use by healthcare providers who care for adult and pediatric patients with group A streptococcal pharyngitis. The guideline updates the 2002 Infectious Diseases Society of America guideline and discusses diagnosis and management, and recommendations are provided regarding antibiotic choices and dosing. Penicillin or amoxicillin remain the treatments of choice, and recommendations are made for the penicillin-allergic patient, which now include clindamycin.
I. How Should the Diagnosis of GAS Pharyngitis Be Established?

Recommendations

1. Swabbing the throat and testing for GAS pharyngitis by rapid antigen detection test (RADT) and/or culture should be performed because the clinical features alone do not reliably discriminate between GAS and viral pharyngitis except when overt viral features like rhinorrhea, cough, oral ulcers, and/or hoarseness are present. In children and adolescents, negative RADT tests should be backed up by a throat culture (strong, high). Positive RADTs do not necessitate a back-up culture because they are highly specific (strong, high).
I. How Should the Diagnosis of GAS Pharyngitis Be Established?

2. Routine use of back-up throat cultures for those with a negative RADT is not necessary for adults in usual circumstances, because of the low incidence of GAS pharyngitis in adults and because the risk of subsequent acute rheumatic fever is generally exceptionally low in adults with acute pharyngitis (strong, moderate). Physicians who wish to ensure they are achieving maximal sensitivity in diagnosis may continue to use conventional throat culture or to back up negative RADTs with a culture.
Where is the PCR recommendation?
Where is the PCR recommendation?

• IDSA guidelines issued in 2012- no FDA approved molecular tests on the market at that time

• Stanford Shulman, chair of the guideline committee and a professor of pediatrics and infectious diseases at Northwestern University Feinberg School of Medicine:
  – "I think the committee will need to take a new look at the field given what has happened in the last few years in terms of the development of molecular testing,“
  – This research on new molecular diagnostic tests "should be taken into account when guidelines are redeveloped," he said.
What test methodology is best for you?

- What patient population are you testing?
  - adult vs. pediatrics
  - Inpatient vs. outpatient

- What are your clinician’s needs?
  - Will new methodologies actually change their practice?

- What is your expected turnaround time?
  - Does it need to be improved?

- Cost and reimbursement
  - In general, molecular assays cost more, but reimbursement is higher

- Administrative buy-in
  - Reagent budgets will increase, so do they understand the benefit?
Overall conclusions

• GAS continues to be a burden on the healthcare system

• Newer molecular techniques have now joined traditional methods (rapid antigen testing, culture) for GAS testing

• Molecular options are now available at point-of-care
  – Substantially reduce TAT

• Guidelines have not yet been updated to reflect this new technology, but this will likely occur in the near future
Questions?

Presented by:
Gregory J. Berry, Ph.D., D(ABMM)
Assistant Professor, Pathology and Laboratory Medicine
Zucker School of Medicine at Hofstra/Northwell
Director, Molecular Diagnostics/ Asst. Director, Infectious Disease Diagnostics
Northwell Health Laboratories

The information in this presentation is provided for educational purposes only and is not legal advice. It is intended to highlight laws you are likely to encounter, but is not a comprehensive review. If you have questions or concerns about a particular instance or whether a law applies, you should consider contacting your attorney.
Thank you